Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-centre, Randomised, Double-blind, Two-way Cross-over Trial Investigating the Bio-equivalence in Healthy Male Subjects of NovoSeven (CP-rFVIIa) and a Formulation of NovoSeven Stable at 25°C (VII25)

NCT01561417 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01561417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01561417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-centre, Randomised, Double-blind, Two-way Cross-over Trial Investigating the Bio-equivalence in Healthy Male Subjects of NovoSeven (CP-rFVIIa) and a Formulation of NovoSeven Stable at 25°C (VII25)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2006
Completion date
September 30, 2006
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bleeding disorder, acquired haemophilia, congenital bleeding disorder, congenital fvii deficiency, glanzmann's disease, haemophilia a with inhibitors, haemophilia b with inhibitors, healthy